Hims expands Lilly partnership and gets JPMorgan Buy at $35; Crinetics SSTR2 NDC; Cerapedics P-15 peptide bone graft Vizient deal; ABC affiliates warn on unregulated peptides.
Read digest →Novo's PIONEER TEENS pediatric T2D oral semaglutide positive; Fractyl REMAIN-1 gut-reset prevents post-GLP-1 weight regain; Roche projects $9B obesity pipeline peak sales.
Read digest →Trump admin extends Medicare GLP-1 Bridge through 2027 with taxpayer dollars after BALANCE collapse; MBX previews three once-monthly peptide candidates; AACR wraps.
Read digest →Trump cancels Medicare GLP-1 pilot after CVS pullout, BPC-157/TB-500 formally exit FDA Cat 2, Avacta PDC shows 3x Enhertu selectivity, 12M lost Wegovy coverage.
Read digest →Amazon enters GLP-1 at $25/mo, Kailera's $625M IPO is biotech's biggest since 2023, Perspective's alpha-PRRT hits 43% ORR, and Sapience's peptide antagonist debuts.
Read digest →Tirzepatide beats semaglutide 21.6% vs 15.4% in SURMOUNT-5, Bicycle PDC hits 40% ORR, 69/74 medspas still sell compounded GLP-1s, AACR peptide vaccines advance.
Read digest →Circle Pharma's CID-078 macrocyclic peptide debuts at AACR clinical plenary; Bicycle's BT5528 HNSCC data; Fedora's FPI-2119 bactericidal profile at ESCMID; HMD-AMP AI finds 37M+ AMPs.
Read digest →GLP-1 pioneers DiMarchi/Tschöp propose non-GLP-1 obesity approach; ESCMID Global opens in Munich; Circle Pharma macrocyclic peptide data at AACR; Scientific American on the peptide craze.
Read digest →AACR 2026 opens with peptide cancer therapies in the spotlight; CAMPER AI-designed peptides kill MRSA persisters; Novo partners with OpenAI for drug discovery.
Read digest →Lilly's Foundayo ACHIEVE-4 data eases FDA concerns with 57% lower death risk; FDA peptide panelists expected to support broader access; non-GLP-1 peptide pipeline advances.
Read digest →FDA schedules July advisory panel on BPC-157 and 6+ peptides for compounding; Hims surges 12%; fewer than 1 in 4 GLP-1 patients stay on treatment after a year.
Read digest →FDA requests Foundayo post-market liver and heart data; Australia's TGA warns on unapproved peptides; PEPITEM matches infliximab for arthritis; AI discovers novel antimicrobials.
Read digest →Stanford discovers brain-targeted peptide rivaling Ozempic without side effects; CNN publishes comprehensive peptide guide; tirzepatide outperforms semaglutide at 12 months.
Read digest →ProPublica investigates risks of FDA peptide reclassification; semaglutide shows mixed results in depression trial; Noom acquires compounding pharmacy to enter peptide market.
Read digest →Apotex wins first generic semaglutide approval, retatrutide aces Phase III, and the Foundayo vs oral Wegovy rivalry intensifies.
Read digest →Lilly launches Foundayo with $1.5B pre-stocked; FDA escalates compounding crackdown; Merck oral peptide PCSK9 inhibitor impresses; Reddit study reveals GLP-1 side effects.
Read digest →Health Canada warns against unauthorized peptides; Nature GWAS links GLP1R variants to weight loss; Indian generic semaglutide surges past Mounjaro.
Read digest →FDA finds no suicide risk with GLP-1s, oral Wegovy draws explosive demand, Lilly's Foundayo launches at $25/month, and a Utah physician is indicted for importing peptides.
Read digest →